GAS5 and neoplasm: The analysis highlighted the significantly improved clinical benefit of the model incorporating GAS5 loss in predicting NMIBC relapse for threshold probabilities ≥25%, compared to the tumour stage, grade and EORTC-risk group model (Fig. 6a).